THE IMPORTANCE OF CIRCULATING TUMOR DNA IN THE ASSESSMENT OF METASTATIC COLORECTAL CANCER TREATMENT EFFECTIVNE
Challenges in cancer detection, prognosis and management are currently being solved by determining circulating tumor DNA (ctDNA). The assessment of this marker has acquired particular importance in metastatic colorectal cancer (mCRC), the systemic treatment of which depends on the RAS gene status, w...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Russian Academy of Sciences, Tomsk National Research Medical Center
2021-10-01
|
| Series: | Сибирский онкологический журнал |
| Subjects: | |
| Online Access: | https://www.siboncoj.ru/jour/article/view/1928 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839579505585291264 |
|---|---|
| author | M. I. Sluzhev V. V. Semiglazov T. Yu. Semiglazova E. V. Tkachenko S. A. Protsenko D. Kh. Latipova S. V. Kondratev N. A. Brish Yu. V. Alekseeva A. M. Belyaev |
| author_facet | M. I. Sluzhev V. V. Semiglazov T. Yu. Semiglazova E. V. Tkachenko S. A. Protsenko D. Kh. Latipova S. V. Kondratev N. A. Brish Yu. V. Alekseeva A. M. Belyaev |
| author_sort | M. I. Sluzhev |
| collection | DOAJ |
| description | Challenges in cancer detection, prognosis and management are currently being solved by determining circulating tumor DNA (ctDNA). The assessment of this marker has acquired particular importance in metastatic colorectal cancer (mCRC), the systemic treatment of which depends on the RAS gene status, which has prognostic and predictive value. However, the possibilities of taking samples from the primary or metastatic lesion for pathomorphological and molecular analysis in CRC are often limited. The determination of ctDNA using liquid biopsy has an advantage over standard biopsy due to its low invasiveness and high availability of the method. Analysis of mutations using ctDNA as well as changes in the level of this marker is a criterion for the effectiveness of systemic treatment, as well as a factor that determines the risk of disease progression. Currently, the potential of using ctDNA to monitor effectiveness of first-and second-line chemotherapy, as well as to predict the development of secondary resistance to EGFR inhibitors (cetuximab and panitumumab) in the first-line treatment and assessment of RAS status for returning to therapy with EGFR inhibitors in the third-line treatment of mCRC is being studied. Several pilot studies have provided evidence of the efficacy of EGFR re-treatment. The modern literature data published in leading peer-reviewed journals in Russian and international scientific citation databases, such as Medline, Elibrary, and PubMed were analyzed. Of the 138 analyzed publications, 56 were used to write this review. |
| format | Article |
| id | doaj-art-7316d304819a481aadb5af0b7ed88cbc |
| institution | Matheson Library |
| issn | 1814-4861 2312-3168 |
| language | Russian |
| publishDate | 2021-10-01 |
| publisher | Russian Academy of Sciences, Tomsk National Research Medical Center |
| record_format | Article |
| series | Сибирский онкологический журнал |
| spelling | doaj-art-7316d304819a481aadb5af0b7ed88cbc2025-08-04T10:33:41ZrusRussian Academy of Sciences, Tomsk National Research Medical CenterСибирский онкологический журнал1814-48612312-31682021-10-0120514916110.21294/1814-4861-2021-20-5-149-161912THE IMPORTANCE OF CIRCULATING TUMOR DNA IN THE ASSESSMENT OF METASTATIC COLORECTAL CANCER TREATMENT EFFECTIVNEM. I. Sluzhev0V. V. Semiglazov1T. Yu. Semiglazova2E. V. Tkachenko3S. A. Protsenko4D. Kh. Latipova5S. V. Kondratev6N. A. Brish7Yu. V. Alekseeva8A. M. Belyaev9N.N. Petrov National Medical Research Center of Oncology; Pavlov First Saint Petersburg State Medical UniversityN.N. Petrov National Medical Research Center of Oncology; Pavlov First Saint Petersburg State Medical UniversityN.N. Petrov National Medical Research Center of Oncology; I.I. Mechnikov North-Western State Medical UniversityN.N. Petrov National Medical Research Center of OncologyN.N. Petrov National Medical Research Center of OncologyN.N. Petrov National Medical Research Center of OncologyN.N. Petrov National Medical Research Center of OncologyN.N. Petrov National Medical Research Center of OncologyN.N. Petrov National Medical Research Center of OncologyN.N. Petrov National Medical Research Center of Oncology; I.I. Mechnikov North-Western State Medical UniversityChallenges in cancer detection, prognosis and management are currently being solved by determining circulating tumor DNA (ctDNA). The assessment of this marker has acquired particular importance in metastatic colorectal cancer (mCRC), the systemic treatment of which depends on the RAS gene status, which has prognostic and predictive value. However, the possibilities of taking samples from the primary or metastatic lesion for pathomorphological and molecular analysis in CRC are often limited. The determination of ctDNA using liquid biopsy has an advantage over standard biopsy due to its low invasiveness and high availability of the method. Analysis of mutations using ctDNA as well as changes in the level of this marker is a criterion for the effectiveness of systemic treatment, as well as a factor that determines the risk of disease progression. Currently, the potential of using ctDNA to monitor effectiveness of first-and second-line chemotherapy, as well as to predict the development of secondary resistance to EGFR inhibitors (cetuximab and panitumumab) in the first-line treatment and assessment of RAS status for returning to therapy with EGFR inhibitors in the third-line treatment of mCRC is being studied. Several pilot studies have provided evidence of the efficacy of EGFR re-treatment. The modern literature data published in leading peer-reviewed journals in Russian and international scientific citation databases, such as Medline, Elibrary, and PubMed were analyzed. Of the 138 analyzed publications, 56 were used to write this review.https://www.siboncoj.ru/jour/article/view/1928metastatic colorectal cancercirculating tumor dnaras mutationsegfr inhibitors |
| spellingShingle | M. I. Sluzhev V. V. Semiglazov T. Yu. Semiglazova E. V. Tkachenko S. A. Protsenko D. Kh. Latipova S. V. Kondratev N. A. Brish Yu. V. Alekseeva A. M. Belyaev THE IMPORTANCE OF CIRCULATING TUMOR DNA IN THE ASSESSMENT OF METASTATIC COLORECTAL CANCER TREATMENT EFFECTIVNE Сибирский онкологический журнал metastatic colorectal cancer circulating tumor dna ras mutations egfr inhibitors |
| title | THE IMPORTANCE OF CIRCULATING TUMOR DNA IN THE ASSESSMENT OF METASTATIC COLORECTAL CANCER TREATMENT EFFECTIVNE |
| title_full | THE IMPORTANCE OF CIRCULATING TUMOR DNA IN THE ASSESSMENT OF METASTATIC COLORECTAL CANCER TREATMENT EFFECTIVNE |
| title_fullStr | THE IMPORTANCE OF CIRCULATING TUMOR DNA IN THE ASSESSMENT OF METASTATIC COLORECTAL CANCER TREATMENT EFFECTIVNE |
| title_full_unstemmed | THE IMPORTANCE OF CIRCULATING TUMOR DNA IN THE ASSESSMENT OF METASTATIC COLORECTAL CANCER TREATMENT EFFECTIVNE |
| title_short | THE IMPORTANCE OF CIRCULATING TUMOR DNA IN THE ASSESSMENT OF METASTATIC COLORECTAL CANCER TREATMENT EFFECTIVNE |
| title_sort | importance of circulating tumor dna in the assessment of metastatic colorectal cancer treatment effectivne |
| topic | metastatic colorectal cancer circulating tumor dna ras mutations egfr inhibitors |
| url | https://www.siboncoj.ru/jour/article/view/1928 |
| work_keys_str_mv | AT misluzhev theimportanceofcirculatingtumordnaintheassessmentofmetastaticcolorectalcancertreatmenteffectivne AT vvsemiglazov theimportanceofcirculatingtumordnaintheassessmentofmetastaticcolorectalcancertreatmenteffectivne AT tyusemiglazova theimportanceofcirculatingtumordnaintheassessmentofmetastaticcolorectalcancertreatmenteffectivne AT evtkachenko theimportanceofcirculatingtumordnaintheassessmentofmetastaticcolorectalcancertreatmenteffectivne AT saprotsenko theimportanceofcirculatingtumordnaintheassessmentofmetastaticcolorectalcancertreatmenteffectivne AT dkhlatipova theimportanceofcirculatingtumordnaintheassessmentofmetastaticcolorectalcancertreatmenteffectivne AT svkondratev theimportanceofcirculatingtumordnaintheassessmentofmetastaticcolorectalcancertreatmenteffectivne AT nabrish theimportanceofcirculatingtumordnaintheassessmentofmetastaticcolorectalcancertreatmenteffectivne AT yuvalekseeva theimportanceofcirculatingtumordnaintheassessmentofmetastaticcolorectalcancertreatmenteffectivne AT ambelyaev theimportanceofcirculatingtumordnaintheassessmentofmetastaticcolorectalcancertreatmenteffectivne AT misluzhev importanceofcirculatingtumordnaintheassessmentofmetastaticcolorectalcancertreatmenteffectivne AT vvsemiglazov importanceofcirculatingtumordnaintheassessmentofmetastaticcolorectalcancertreatmenteffectivne AT tyusemiglazova importanceofcirculatingtumordnaintheassessmentofmetastaticcolorectalcancertreatmenteffectivne AT evtkachenko importanceofcirculatingtumordnaintheassessmentofmetastaticcolorectalcancertreatmenteffectivne AT saprotsenko importanceofcirculatingtumordnaintheassessmentofmetastaticcolorectalcancertreatmenteffectivne AT dkhlatipova importanceofcirculatingtumordnaintheassessmentofmetastaticcolorectalcancertreatmenteffectivne AT svkondratev importanceofcirculatingtumordnaintheassessmentofmetastaticcolorectalcancertreatmenteffectivne AT nabrish importanceofcirculatingtumordnaintheassessmentofmetastaticcolorectalcancertreatmenteffectivne AT yuvalekseeva importanceofcirculatingtumordnaintheassessmentofmetastaticcolorectalcancertreatmenteffectivne AT ambelyaev importanceofcirculatingtumordnaintheassessmentofmetastaticcolorectalcancertreatmenteffectivne |